PPARs and molecular mechanisms of transrepression

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 8, 2007, Pages 926-935

  Ricote, Mercedes ^a   Glass, Christopher K ^b  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Coactivators; Corepressors; Inflammation; Macrophage; Peroxisome proliferator activated receptors; Transrepression

Indexed keywords

FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOTRANSFERASE; PIRINIXIC ACID; ROSIGLITAZONE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANTIINFLAMMATORY ACTIVITY; CELL SPECIFICITY; DRUG MECHANISM; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; KNOCKOUT MOUSE; MACROPHAGE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIOSENSING TECHNIQUES; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; IMMUNITY; INFLAMMATION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

MUS;

EID: 34547603895     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.02.013     Document Type: Review

References (111)

1. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat. Med. 10 (2004) 355-361
2. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
3. Daynes R.A., and Jones D.C. Emerging roles of ppars in inflammation and immunity. Nat. Rev., Immunol. 2 (2002) 748-759
4. Kostadinova R., Wahli W., and Michalik L. PPARs in diseases: control mechanisms of inflammation. Curr. Med. Chem. 12 (2005) 2995-3009
5. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
6. Willson T.M., Lambert M.H., and Kliewer S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem. 70 (2001) 341-367
7. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
8. Fruchart J.C., Duriez P., and Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10 (1999) 245-257
9. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270 (1995) 12953-12956
10. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., and Lehmann J.M. The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones. J. Med. Chem. 39 (1996) 665-668
11. Krey G., Keller H., Mahfoudi A., Medin J., Ozato K., Dreyer C., and Wahli W. Xenopus peroxisome proliferator activated receptors: genomic organization, response element recognition, heterodimer formation with retinoid X receptor and activation by fatty acids. J. Steroid. Biochem. Mol. Biol. 47 (1993) 65-73
12. IJpenberg A., Jeannin E., Wahli W., and Desvergne B. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J. Biol. Chem. 272 (1997) 20108-20117
13. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., and Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116 (2006) 3015-3025
14. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., and Wahli W. The PPARa-leukotriene B4 pathway to inflammation control. Nature 384 (1996) 39-43
15. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
16. Jiang C., Ting A.T., and Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
17. Marx N., Schönbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83 (1998) 1097-1103
18. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., and Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393 (1998) 790-793
19. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., and Evans R.M. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302 (2003) 453-457
20. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., and Glass C.K. PPARγ and PPARd negatively regulate specific subsets of lipopolysaccharide and IFNγ target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6712-6717
21. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., and Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 (2005) 707-721
22. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
23. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054
24. Xu X., Otsuki M., Saito H., Sumitani S., Yamamoto H., Asanuma N., Kouhara H., and Kasayama S. PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells. Endocrinology 142 (2001) 3332-3339
25. Marx N., Mackman N., Schonbeck U., Yilmaz N., Hombach V., Libby P., and Plutzky J. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103 (2001) 213-219
26. Neve B.P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J.C., Duriez P., Staels B., and Jude B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 103 (2001) 207-212
27. Delerive P., Gervois P., Fruchart J.C., and Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275 (2000) 36703-36707
28. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., Princen H.M., Kooistra T., and Staels B. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood 93 (1999) 2991-2998
29. Madej A., Okopien B., Kowalski J., Zielinski M., Wysocki J., Szygula B., Kalina Z., and Herman Z.S. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb. Int. J. Clin. Pharmacol. Ther. 36 (1998) 345-349
30. Marx N., Kehrle B., Kohlhammer K., Grub M., Koenig W., Hombach V., Libby P., and Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90 (2002) 703-710
31. Jones D.C., Ding X., and Daynes R.A. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J. Biol. Chem. 277 (2002) 6838-6845 (Electronic publication 2001 Nov 28)
32. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., and Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 168 (2002) 2795-2802
33. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 172 (2004) 5790-5798
34. Cunard R., DiCampli D., Archer D.C., Stevenson J.L., Ricote M., Glass C.K., and Kelly C.J. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo. J. Immunol. 169 (2002) 6806-6812
35. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273 (1998) 32833-32841
36. Xu J., Storer P.D., Chavis J.A., Racke M.K., and Drew P.D. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J. Neurosci. Res. 81 (2005) 403-411
37. Duez H., Chao Y.S., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton C.A., Tedgui A., Fruchart J.C., Fievet C., Wright S.D., and Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277 (2002) 48051-48057
38. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A., Davis R.A., Willson T.M., Witztum J.L., Palinski W., and Glass C.K. Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPAR α, β/δ, and γ. J. Clin. Invest. 114 (2004) 1564-1576
39. Gervois P., Vu-Dac N., Kleemann R., Kockx M., Dubois G., Laine B., Kosykh V., Fruchart J.C., Kooistra T., and Staels B. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J. Biol. Chem. 276 (2001) 33471-33477
40. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Murakami A., and Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61 (2001) 2424-2428
41. Michalik L., Desvergne B., Basu-Modak S., Tan N.S., and Wahli W. Nuclear hormone receptors and mouse skin homeostasis: implication of PPARbeta. Horm. Res. 54 (2000) 263-268
42. Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., Peters J.M., Kaya G., Gonzalez F.J., Zakany J., Metzger D., Chambon P., Duboule D., and Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154 (2001) 799-814
43. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., Flanigan A., Murthy S., Lazar M.A., and Wu G.D. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J. Clin. Invest. 104 (1999) 383-389
44. Desreumaux P., Dubuquoy L., Nutten S., Peuchmaur M., Englaro W., Schoonjans K., Derijard B., Desvergne B., Wahli W., Chambon P., Leibowitz M.D., Colombel J.F., and Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193 (2001) 827-838
45. Li A., Brown K., Silvestre M., Willson T., Palinski W., and Glass C. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. CIin. Invest. 106 (2000) 523-531
46. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., and Tontonoz P. A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7 (2001) 161-171
47. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., and Law R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 365-371
48. Niino M., Iwabuchi K., Kikuchi S., Ato M., Morohashi T., Ogata A., Tashiro K., and Onoe K. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-gamma. J. Neuroimmunol. 116 (2001) 40-48
49. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., Drew P.D., and Racke M.K. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy- Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168 (2002) 2508-2515
50. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., Landreth G.E., Pershadsingh H.A., Weinberg G., and Heneka M.T. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51 (2002) 694-702
51. Setoguchi K., Misaki Y., Terauchi Y., Yamauchi T., Kawahata K., Kadowaki T., and Yamamoto K. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J. Clin. Invest. 108 (2001) 1667-1675
52. Ellis C.N., Varani J., Fisher G.J., Zeigler M.E., Pershadsingh H.A., Benson S.C., Chi Y., and Kurtz T.W. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch. Dermatol. 136 (2000) 609-616
53. Kuenzli S., and Saurat J.H. Effect of Topical PPARbeta/delta and PPARgamma Agonists on Plaque Psoriasis. A Pilot Study. Dermatology 206 (2003) 252-256
54. Sundararajan S., Jiang Q., Heneka M., and Landreth G. PPARgamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 49 (2006) 136-144
55. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
56. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153 (1998) 17-23
57. Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., Ishida T., and Takahara J. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett. 454 (1999) 27-30
58. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., and Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN- gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 164 (2000) 6503-6508
59. Bernardo A., Levi G., and Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. 12 (2000) 2215-2223
60. Bernardo A., and Minghetti L. PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006) 93-109
61. Cunard R., Eto Y., Muljadi J.T., Glass C.K., Kelly C.J., and Ricote M. Repression of IFN-gamma expression by peroxisome proliferator-activated receptor gamma. J. Immunol. 172 (2004) 7530-7536
62. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., and Farrar W.L. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J. Biol. Chem. 275 (2000) 4541-4544
63. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.C., Najib J., Duriez P., and Staels B. Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85 (1999) 394-402
64. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., and Glass C.K. Interleukin-4-dependent production of PPAR-g ligands in macrophages by 12/15-lipoxygenase. Nature 400 (1999) 378-382
65. Barish G.D., Downes M., Alaynick W.A., Yu R.T., Ocampo C.B., Bookout A.L., Mangelsdorf D.J., and Evans R.M. A Nuclear Receptor Atlas: macrophage activation. Mol. Endocrinol. 19 (2005) 2466-2477
66. Straus D.S., Pascual G., Li M., Welch J.S., Ricote M., Hsiang C.H., Sengchanthalangsy L.L., Ghosh G., and Glass C.K. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4844-4849
67. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403 (2000) 103-108
68. Castrillo A., Diaz-Guerra M.J., Hortelano S., Martin-Sanz P., and Bosca L. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Mol. Cell. Biol. 20 (2000) 1692-1698
69. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
70. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., and Freeman M.W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7 (2001) 41-47
71. Ding G., Cheng L., Qin Q., Frontin S., and Yang Q. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell Cardiol. 40 (2006) 821-828
72. Glass C.K., and Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14 (2000) 121-141
73. McKenna N.J., and O'Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108 (2002) 465-474
74. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 20 (2006) 1405-1428
75. Glass C.K., and Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev., Immunol. 6 (2006) 44-55
76. Pascual G., and Glass C.K. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17 (2006) 321-327
77. Dowell P., Ishmael J.E., Avram D., Peterson V.J., Nevrivy D.J., and Leid M. Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. J. Biol. Chem. 274 (1999) 15901-15907
78. Jepsen K., Hermannson O., Thandi O., Gleiberman A., Lunyak V., Kurokawa R., Kumar V., Liu F., Seto E., Hedrick S., Mandel G., Glass C., Rose D., and Rosenfeld M. Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102 (2000) 753-763
79. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstrom M., Glass C.K., et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 (1995) 397-404
80. Chen J.D., and Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 (1995) 454-457
81. Li J., Wang J., Nawaz Z., Liu J., Qin J., and Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19 (2000) 4342-4350
82. Yoon H.G., Chan D.W., Huang Z.Q., Li J., Fondell J.D., Qin J., and Wong J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 22 (2003) 1336-1346
83. Hu X., and Lazar M. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 (1999) 93-96
84. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395 (1998) 137-143
85. Perissi V., Staszewski L.M., McInerney E.M., Kurokawa R., Krones A., Rose D.W., Lambert M.H., Milburn M.V., Glass C.K., and Rosenfeld MG M.G. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev. 13 (1999) 3198-3208
86. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., McKee D.D., Galardi C.M., Plunket K.D., Nolte R.T., Parks D.J., Moore J.T., Kliewer S.A., Willson T.M., and Stimmel J.B. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 (2002) 813-817
87. Perissi V., Aggarwal A., Glass C.K., Rose D.W., and Rosenfeld M.G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 116 (2004) 511-526
88. Hoberg J.E., Yeung F., and Mayo M.W. SMRT derepression by the IκB kinase α: a prerequisite to NF-κB transcription and survival. Mol. Cell 16 (2004) 245-255
89. Ogawa S., Lozach J., Jepsen K., Sawka-Verhelle D., Perissi V., Sasik R., Rose D.W., Johnson R.S., Rosenfeld M.G., and Glass C.K. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14461-14466
90. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., and Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 (2005) 759-763
91. Li M., Pascual G., and Glass C. Peroxisome proliferator-activated receptor y-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20 (2000) 4699-4707
92. Kelly D., Campbell J.I., King T.P., Grant G., Jansson E.A., Coutts A.G., Pettersson S., and Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat. Immunol. 5 (2004) 104-112 (Electronic publication 2003 Dec 21)
93. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Staels B., and Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J. Biol. Chem. 279 (2004) 16154-16160
94. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., and Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv. Exp. Med. Biol. 544 (2003) 181-196
95. Kleemann R., Gervois P.P., Verschuren L., Staels B., Princen H.M., and Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101 (2003) 545-551
96. Kleemann R., Verschuren L., de Rooij B.J., Lindeman J., de Maat M.M., Szalai A.J., Princen H.M., and Kooistra T. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103 (2004) 4188-4194
97. Chung S.W., Kang B.Y., Kim S.H., Pak Y.K., Cho D., Trinchieri G., and Kim T.S. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J. Biol. Chem. 275 (2000) 32681-32687
98. Zingarelli B., Sheehan M., Hake P.W., O'Connor M., Denenberg A., and Cook J.A. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J. Immunol. 171 (2003) 6827-6837
99. Goetze S., Xi X.P., Kawano H., Gotlibowski T., Fleck E., Hsueh W.A., and Law R.E. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 33 (1999) 798-806
100. Goetze S., Xi X.P., Graf K., Fleck E., Hsueh W.A., and Law R.E. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Lett. 452 (1999) 277-282
101. Goetze S., Kintscher U., Kim S., Meehan W.P., Kaneshiro K., Collins A.R., Fleck E., Hsueh W.A., and Law R.E. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J. Cardiovasc. Pharmacol. 38 (2001) 909-921
102. Goetze S., Eilers F., Bungenstock A., Kintscher U., Stawowy P., Blaschke F., Graf K., Law R.E., Fleck E., and Grafe M. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem. Biophys. Res. Commun. 293 (2002) 1431-1437
103. Akaike M., Che W., Marmarosh N.L., Ohta S., Osawa M., Ding B., Berk B.C., Yan C., and Abe J. The hinge-helix 1 region of peroxisome proliferator-activated receptor gamma1 (PPARgamma1) mediates interaction with extracellular signal-regulated kinase 5 and PPARgamma1 transcriptional activation: involvement in flow-induced PPARgamma activation in endothelial cells. Mol. Cell. Biol. 24 (2004) 8691-8704
104. Jones D.C., Ding X., Zhang T.Y., and Daynes R.A. Peroxisome proliferator-activated receptor alpha negatively regulates T-bet transcription through suppression of p38 mitogen-activated protein kinase activation. J. Immunol. 171 (2003) 196-203
105. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., Percevault F., Fruchart J.C., Dombrowicz D., Glineur C., and Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ. Res. 98 (2006) 361-369
106. Blanquart C., Mansouri R., Paumelle R., Fruchart J.C., Staels B., and Glineur C. The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol. Endocrinol. 18 (2004) 1906-1918
107. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.-C., Heyman R., Rose D., Glass C., and Rosenfeld M. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85 (1996) 403-414
108. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., and Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 25 (2007) 57-70
109. Liu B., Mink S., Wong K.A., Stein N., Getman C., Dempsey P.W., Wu H., and Shuai K. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5 (2004) 891-898
110. Jackson P.K. A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev. 15 (2001) 3053-3058
111. Ohshima T., Koga H., and Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor γ Is modulated by SUMO-1 modification. J. Biol. Chem. 279 (2004) 29551-29557